Impact of China’s Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease
By: Miao Wang, Jing Liu, Brandon K. Bellows, Yue Qi, Jiayi Sun, Jun Liu, Andrew E. Moran and Dong Zhao
References
- Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990–2013: A systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2016; 387(10015): 251–272. DOI: 10.1016/S0140-6736(15)00551-6
- Li Y, Zeng X, Liu J, et al. Can China achieve a one-third reduction in premature mortality from non-communicable diseases by 2030? Bmc Med. 2017; 15(1): 132. DOI: 10.1186/s12916-017-0894-5
- Joint committee for developing Chinese guidelines on prevention and treatment of dyslipidemia in adults. Guideline on the prevention and treatment of dyslipidemia in Chinese adults (2016-Update). Chinese Journal of Cardiology. 2016; 44(10): 833–853. DOI: 10.3760/cma.j.issn.0253-3758.2016.10.005
- Luo JY, Ma YT, Yu ZX, et al. Prevalence, awareness, treatment and control of dyslipidemia among adults in northwestern China: The cardiovascular risk survey. Lipids Health Dis. 2014; 13: 4. DOI: 10.1186/1476-511X-13-4
- Huang Y, Gao L, Xie X, et al. Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control. Popul Health Metr. 2014; 12(1): 28. DOI: 10.1186/s12963-014-0028-7
- Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009; 150(4): 243–254. DOI: 10.7326/0003-4819-150-4-200902170-00005
- Lazar LD, Pletcher MJ, Coxson PG, et al. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011; 124(2): 146–153. DOI: 10.1161/CIRCULATIONAHA.110.986349
- Greving JP, Visseren FL, de Wit GA, et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ (Clinical research ed.). 2011; 342: d1672. DOI: 10.1136/bmj.d1672
- McConnachie A, Walker A, Robertson M, et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: A record linkage study. Eur Heart J. 2014; 35(5): 290–298. DOI: 10.1093/eurheartj/eht232
- Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015; 314(2): 142–150. DOI: 10.1001/jama.2015.6822
- Heller DJ, Coxson PG, Penko J, et al. Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke. Circulation; 2017. DOI: 10.1161/CIRCULATIONAHA.117.027067
- Burgers LT, Nauta ST, Deckers JW, et al. Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment? Int J Cardiol. 2014; 176(3): 980–987. DOI: 10.1016/j.ijcard.2014.08.134
- Integrated management platform of Beijing medicine sunshine purchase.
http://210.73.89.76/ServiceSelect/GetServiceSelectList . (accessed 5 December 2018). - Beijing Medicine Sunshine Purchasing. Notice on announcement of the bidding result of centralized medicine procurement in “4+7” cities.
https://yp.bjmbc.org.cn/view/index/detail.html?id=ZDAT00000000000001682913 .(accessed 9 April 2019). - Miao W, Jing L, Dong Z. New risk assessment tool of atherosclerotic cardiovascular disease for Chinese adults. Chinese Journal of Cardiology. 2018; (2): 87–91. DOI: 10.3760/cma.j.issn.0253-3758.2018.02.003
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013; 34(17): 1279–1291. DOI: 10.1093/eurheartj/eht055
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73(24): e285–e350. DOI: 10.1016/j.jacc.2018.11.003
- Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet (London, England). 2012; 380(9841): 581–590. DOI: 10.1016/S0140-6736(12)60367-5
- Sun H, Wu X, Yang X, et al. Multivariate analysis of the cost on diabetes mellitus patients. Chinese Journal of Prevention and Control of Chronic Non-Communicable Diseases. 2002; 10(2): 62–64. DOI: 10.3969/j.issn.1004-6194.2002.02.007
- Ministry of Health of the People’s Republic of China.China’ Health Statistics Yearbook 2018. Beijing: China Union Medical University Press; 2018.
- Chun-yan LI, Wei-yan J. Economic burden among cardiovascular patients of middle-aged and elderly: An empirical analysis based on China Health and Retirement Longitudinal Survey data. Chinese Journal of Health Policy. 2017; 10(5): 75–80. DOI: 10.3969/j.issn.1674-2982.2017.05.013
- Jieyu W.
The study on the economic burden of stroke patients and its influencing factors in Henan province . MPH thesis. Zhengzhou University; Zhengzhou; 2017. - Karlson BW, Wiklund O, Palmer MK, et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: Results from VOYAGER. European Heart Journal. Cardiovascular Pharmacotherapy. 2016; 2(4): 212–217. DOI: 10.1093/ehjcvp/pvw006
- Zhang X, Liu J, Wang M, et al. Twenty-year epidemiologic study on LDL-C levels in relation to the risks of atherosclerotic event, hemorrhagic stroke, and cancer death among young and middle-aged population in China. J Clin Lipidol. 2018; 12(5): 1179–1189. DOI: 10.1016/j.jacl.2018.06.011
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA. 2016; 316(10): 1093–1103. DOI: 10.1001/jama.2016.12195
- Trading Economics. China Inflation Rate.
https://tradingeconomics.com/china/inflation-cpi (accessed 6 Feb 2020). - Organization for Economic Co-Operation and Development. 4.PPPs and Exchange rates.
https://stats.oecd.org/Index.aspx?DataSetCode=SNA_TABLE4 (accessed 6 Feb 2020). - Ting Z, Hai-jing G, Guo-en G, et al. Health-related quality of life for disease population in China based on EQ-5D: A systematic review. Chin J Evid-based Med. 2016; 02: 135–142.
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (London, England). 2017; 390(10100): 1211–1259. DOI: 10.1016/S0140-6736(17)32154-2
- National Bureau of Statistics. Statistical communiqué of the People’s Republic of China on the 2018 national economic and social development.
http://www.stats.gov.cn/tjsj/zxfb/201902/t20190228_1651265.html (accessed 28 Feb 2019). - Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013; 16(2): e1–e5. DOI: 10.1016/j.jval.2013.02.010
- Aarnio E, Korhonen MJ, Huupponen R, et al. Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence—Estimates from the Finnish prescription register. Atherosclerosis. 2015; 239(1): 240–247. DOI: 10.1016/j.atherosclerosis.2014.12.059
- Jiang Y, Ni W. Economic evaluation of the 2016 Chinese guideline and alternative risk thresholds of initiating statin therapy for the management of atherosclerotic cardiovascular disease. Pharmacoeconomics. 2019; 37(7): 943–952. DOI: 10.1007/s40273-019-00791-8
- Sunshine Medical Procurement All-In-One. Press conference for extending and promoting the centralized medicine procurement policy in nationwide.
http://www.yyzbsw.sh.cn/gjsdcg/2020/01/17/9262.shtml (accessed 6 March 2020). - Sunshine Medical Procurement All-In-One. Announcement for extending the centralized medicine procurement policy in nationwide.
http://www.yyzbsw.sh.cn/gjsdcg/2019/12/29/9205.shtml (accessed 6 March 2020). - Disease prevention and control bureau of the National Health and Family Planning Commission.
Report on Chinese resident’s chronic disease and nutrition . Beijing; People’s Medical Publishing House; 2015. - Wu-jie Z, Xiao-dong G, Chun-xia M, et al. A comparative analysis of centralized drug procurement in China. Chinese Journal of Health Policy. 2016; 9(9): 35–40. DOI: 10.3969/j.issn.1674-2982.2016.09.007
DOI: https://doi.org/10.5334/gh.830 | Journal eISSN: 2211-8179
Language: English
Submitted on: May 27, 2020
Accepted on: May 27, 2020
Published on: Jun 25, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2020 Miao Wang, Jing Liu, Brandon K. Bellows, Yue Qi, Jiayi Sun, Jun Liu, Andrew E. Moran, Dong Zhao, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.